CD274 and neoplasm: At present, only PD-L1 positivity, high microsatellite instability (MSI-H)/mismatch repair deficiency (dMMR) and high tumor mutational burden (TMB-H) are clinically-approved biomarkers for ICI patient selection [5–7].